Serum levels of the cytokines IL-1 beta, IL-6 and ICAM-1 after I-131-treatment of Graves' disease and nodular goiter

Citation
B. Nygaard et al., Serum levels of the cytokines IL-1 beta, IL-6 and ICAM-1 after I-131-treatment of Graves' disease and nodular goiter, HORMONE MET, 32(7), 2000, pp. 283-287
Citations number
20
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
HORMONE AND METABOLIC RESEARCH
ISSN journal
00185043 → ACNP
Volume
32
Issue
7
Year of publication
2000
Pages
283 - 287
Database
ISI
SICI code
0018-5043(200007)32:7<283:SLOTCI>2.0.ZU;2-5
Abstract
Cytokines might be involved in the immunological flare up, seen in some pat ients after I-131-treatment. Therefore, we measured serum levels of interle ukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-6 soluble recept or (IL-6sR) and Intercellular-adhesion-molecule-1 (ICAM-1) as well as tumor necrosis factor (TNF-alpha) after I-131-treatment of Graves' disease and n odular goiter. Seven patients with Craves' disease, eight with toxic nodula r goiter and seven with non-toxic nodular goiter, were followed after I-131 -treatment. The patients were treated in the euthyroid state. Blood samples were drawn at day 0, 4, 7, 21 and after 3 months. Significant increases we re seen in free T-4 index (FT4II), free T-3 index (FT3I) and thyroglobulin (Tg) within the first weeks, and TSH simultaneously decreased. None of the cytokines demonstrated any change during follow-up, neither in the entire g roup nor in subgroups. FT4I and FT3I correlated significantly to ICAM-1. In conclusion, our data suggest that there does not seem to be prolonged cyto kine activation after I-131-treatment for thyroid disorders.